Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 12, 2010 David Meier	Would Jeremy Grantham Buy Travelzoo? I have to believe Grantham would certainly give Travelzoo a good, hard look. And you and I should, too.
The Motley Fool August 11, 2010 David Meier	Would Jeremy Grantham Buy ADTRAN? The company currently earns a return on invested capital that is higher than its cost of capital. Fools love companies that take shareholder capital and create value with it.
The Motley Fool August 12, 2010 David Meier	Would Jeremy Grantham Buy Tractor Supply Company? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains.
The Motley Fool August 12, 2010 David Meier	Would Jeremy Grantham Buy T. Rowe Price? The company earns a return on invested capital that is higher than its cost of capital. Fools love companies that take shareholder capital and create value with it.
The Motley Fool August 11, 2010 David Meier	Would Jeremy Grantham Buy Copart? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains.
The Motley Fool August 10, 2010 David Meier	Would Jeremy Grantham Buy Alcon? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains.
The Motley Fool July 28, 2010 Matthew Argersinger	7 High-Quality Stocks for 7 Lean Years Worried about the future? Here are seven stocks that should outperform big time.
The Motley Fool August 6, 2010 Bryan Hinmon	Moat Report Card: Medtronic This medical supplier's definitely got a heartbeat.
The Motley Fool August 12, 2010 David Meier	Is Google Growing Foolishly? Internet search provider Google has produced Foolish growth for some time now.
The Motley Fool August 10, 2010 David Meier	Is Apple Growing Foolishly? There's a right way and a wrong way for businesses to grow.
The Motley Fool July 28, 2004 Bill Mann	Grantham: Prepare for Pain The highly successful long-term investor and principal for investment management firm Grantham, Mayo & Van Otterloo warns of impending peril in the U.S. markets.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool October 11, 2011 Andrew Tonner	Opportunity Lying in Plain Sight Taking a page from one of the best investors out there helps us find stocks worth examining. Take a look at this list.
The Motley Fool February 10, 2010 Matt Koppenheffer	Forget the Bears: There Are Still Stocks You Should Be Buying Here's how you can find great opportunities in the stock market right now.
The Motley Fool August 12, 2010 David Meier	Is Research In Motion Growing Foolishly? Research in Motion's track record of creating value as it grows makes it well worth considering.
The Motley Fool July 20, 2005 Stephen D. Simpson	Hey, Jude! Party Hearty St. Jude's ICD (implantable cardioverter defibrillator) business is on fire and fueling strong profit growth for this medical device maker. Whether your cut-off makes St. Jude a mid-cap or a large-cap, this company is certainly growing -- and the stock's valuation reflects that.
BusinessWeek August 13, 2007	Life In A Time Of Bubbles Money manager Jeremy Grantham says overpriced assets are everywhere. He's prepared for a global reckoning.
The Motley Fool August 30, 2010 Jim Royal	Is Microsoft Doing Right By Investors? Discover one of the Oracle of Omaha's favorite ways to size up a stock. He calculates return on invested capital to help determine whether a company has an economic moat
Real Estate Portfolio Mar/Apr 2004 Christopher M. Wright	Q&A with Jeremy Grantham Real Estate Portfolio recently asked celebrated investment manager and noted bear Jeremy Grantham, chairman of Grantham, Mayo, Van Otterloo & Co. LLC, to share his thoughts on the capital markets and REIT stocks.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool August 16, 2010 Alex Dumortier	Why Does the Market Hate Blue Chips? Blue-chip stocks are cheap, but why?
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool January 27, 2010 Amanda B. Kish	Is a New Bubble Forming? At least one prominent guru is back to predicting doom and gloom, in the shape of yet another asset bubble forming right this very moment.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.
BusinessWeek March 22, 2004 Robert Barker	St. Jude: An Insider Sign To Investors? St. Jude, the patron saint of lost causes, rarely has needed to look out for his namesake, St. Jude Medical (STJ ). Since its birth in 1976, this maker of artificial heart valves, defibrillators, catheters, and sundry other cardiac devices has led a blessed life. It's in excellent health today. So why are insiders dumping the stock?
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool July 25, 2011 Jordan DiPietro	Should You Retire With St. Jude? I can't decide for you whether or not this is the best stock for retirement, but it has passed all four tests, which is pretty impressive.
The Motley Fool April 11, 2008 Brian Orelli	St. Jude's Heartfelt Acquisition Medical-device maker St. Jude purchases tiny EP MedSystems.
The Motley Fool August 30, 2010 Jim Royal	Does Wal-Mart Pass Buffett's Test? Discover one of the Oracle of Omaha's favorite ways to size up a stock.
Registered Rep. July 12, 2011 Stan Luxenberg	Some High-Profile Mutual Fund Managers Are on a Buyer's Strike At a time when the markets are plagued by sluggish economic growth and unnerving debt burdens, some prominent funds are avoiding major categories of stocks or bonds.
The Motley Fool August 25, 2011 Jim Royal	Does Crox Earn Its Keep? Crocs' returns on invested capital have fluctuated over the past five years, and are currently lower than they were five years ago.
Financial Advisor August 2004 Evan Simonoff	Bear Brawl Comes Up Short FPA Capital's Robert Rodriguez and Grantham Mayo's Jeremy Grantham faced off to argue with a bond fund maven, Citigroup's Joe Deane, who was much more bullish on stocks than on his own asset class. The exchange took place at Morningstar's annual mutual fund conference.
The Motley Fool August 25, 2011 Jim Royal	Does Western Refining Earn Its Keep? Western Refining has improved its returns on invested capital dramatically from three years ago, but they are down from five years ago.
The Motley Fool August 12, 2009 Alex Dumortier	This "Junk Rally" Could Burn Stock Investors The recent rally is built on shaky foundations; indeed, it is the poorer-quality companies that have experienced the largest gains. This has serious implications for all prudent investors.
The Motley Fool September 1, 2010 Jim Royal	Is Schlumberger Doing Right By Investors? Discover one of the Oracle of Omaha's favorite ways to size up a stock, using Schlumberger as an example.
BusinessWeek May 13, 2010	Beware a Bernanke-Fueled Market Bubble Jeremy Grantham sees just a small chance of a strong recovery -- but finds high-quality stocks cheap
BusinessWeek January 6, 2011 Charles Stein	Sticking with Large-Cap Stocks for 2011 Three noted money managers are holding to their view that high-quality, large-cap stocks offer the best values in the market.
The Motley Fool December 30, 2005	Foolish Fundamentals: Return on Invested Capital Investors, learn to measure how much value a company creates.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
The Motley Fool August 23, 2010 James Early	Is Frontier Worth Its Salt? How does this company look on this critical metric?
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool August 25, 2011 Jim Royal	Does CR Bard Earn Its Keep? CR Bard has not seen significant changes in its returns on invested capital over the past five years, which suggests that it is effectively maintaining its competitive position.
The Motley Fool August 24, 2011 Jim Royal	Does Flowserve Earn Its Keep? Flowserve showed the kind of steady growth in its returns on invested capital that we like to see until it suffered a sharp decline on its returns in the last four quarters.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool August 23, 2011 Jim Royal	Does EarthLink Earn Its Keep? Here's one of Buffett's favorite metrics for evaluating companies: Return on invested capital. How does Earthlink do?
The Motley Fool August 30, 2010 Jim Royal	Does ExxonMobil Pass Buffett's Test? Discover one of the Oracle of Omaha's favorite ways to size up a stock, with ExxonMobil as the example.
The Motley Fool August 17, 2007 David Meier	The Magic of ROIC It's amazing what ROIC, return on invested capital, can do for your ability to value a company. Although no one metric should be used exclusively, ROIC is as close to perfect as you may be able to get. Here's why.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.